Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07644364
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionNovartis PharmaceuticalsNot Yet RecruitingPhase 1
NCT07644364Not Yet Recruiting
Phase 1
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Press...Novartis Pharmaceuticals
NCT07644455
Percutaneous Biopsy After Neoadjuvant Chemotherapy.Instituto do Cancer do Estado de São PauloNot Yet RecruitingNot Applicable
NCT07644455Not Yet Recruiting
Not Applicable
Percutaneous Biopsy After Neoadjuvant Chemotherapy.Instituto do Cancer do Es...
NCT07645807
An Investigator-Initiated, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.Sichuan Credit Pharmaceutical Co., Ltd.Not Yet RecruitingNot Applicable
NCT07645807Not Yet Recruiting
Not Applicable
An Investigator-Initiated, Randomized, Double-Blind, Double-Dummy Study to Evalu...Sichuan Credit Pharmaceut...
NCT07644585
A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and NeckIBA Proton Therapy, Inc.Not Yet RecruitingNot Applicable
NCT07644585Not Yet Recruiting
Not Applicable
A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Ca...IBA Proton Therapy, Inc.
NCT07644702
WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial Participation for Rural and Low Income WomenMayo ClinicRecruitingNot Applicable
NCT07644702Recruiting
Not Applicable
WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical...Mayo Clinic
NCT07644650
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant TumorsMabsoft Therapeutics (Australia) Pty. Ltd.Not Yet RecruitingPhase 1
NCT07644650Not Yet Recruiting
Phase 1
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant TumorsMabsoft Therapeutics (Aus...
NCT07644078
Clinical Examination of Cavovarus FeetRoyal National Orthopaedic Hospital NHS TrustRecruiting
NCT07644832
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyShanghai RAAS Blood Products Co., Ltd.RecruitingPhase 1
NCT07644832Recruiting
Phase 1
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tol...Shanghai RAAS Blood Produ...
NCT07645066
Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node DysfunctionShanghai Tong Ren HospitalNot Yet RecruitingNot Applicable
NCT07645066Not Yet Recruiting
Not Applicable
Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients...Shanghai Tong Ren Hospita...
NCT07645950
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Montpellier - Val d'AurelleNot Yet Recruiting
NCT07645950Not Yet Recruiting
—
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Mon...
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D CompanyNot Yet RecruitingPhase 1
NCT07645222Not Yet Recruiting
Phase 1
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D Com...
NCT07644390
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal Surgery Using Longitudinal Indices of Routine Blood Tests: A Single-Center Retrospective Cohort StudySixth Affiliated Hospital, Sun Yat-sen UniversityCompleted
NCT07644390Completed
—
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal...Sixth Affiliated Hospital...
NCT07645651
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic CancerCarrick Therapeutics LimitedNot Yet RecruitingPhase 1
NCT07645651Not Yet Recruiting
Phase 1
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectabl...Carrick Therapeutics Limi...
NCT07645690
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell CarcinomaChinese PLA General HospitalRecruitingEarly Phase 1
NCT07645690Recruiting
Early Phase 1
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Meta...Chinese PLA General Hospi...
NCT07643935
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of ResponseCentral Hospital, Nancy, FranceNot Yet Recruiting
NCT07643935Not Yet Recruiting
—
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timin...Central Hospital, Nancy,...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646028
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLCNot Yet RecruitingPhase 1
NCT07646028Not Yet Recruiting
Phase 1
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLC
NCT07644884
Effects of Deltoid Strengthening Exercises in Patients With Adhesive CapsulitisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07644884Not Yet Recruiting
Not Applicable
Effects of Deltoid Strengthening Exercises in Patients With Adhesive CapsulitisRiphah International Univ...
NCT07643883
IPACK vs Adductor Magnus Plane Block Added to Adductor Canal Block for Total Knee ArthroplastyAtaturk UniversityCompletedNot Applicable
NCT07643883Completed
Not Applicable
IPACK vs Adductor Magnus Plane Block Added to Adductor Canal Block for Total Kne...Ataturk University
Result Breakdown
Not yet recruiting12 (60%)
Recruiting5 (25%)
Completed3 (15%)
Phase 17 (35%)
not_applicable7 (35%)
Not Specified4 (20%)
Early Phase 11 (5%)
Phase 21 (5%)